7-(4-Acetyl-3-hydroxy-2-propylphenoxy)heptane nitrile | 92518-08-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 7-(4-Acetyl-3-hydroxy-2-propylphenoxy)heptane nitrile
• 英文别名: 7-(4-acetyl-3-hydroxy-2-propylphenoxy)heptanenitrile
• CAS: 92518-08-6
• 化学式: C₁₈H₂₅NO₃
• 分子量: 303.401
• InChiKey: IHAUFAWTBDBKSS-UHFFFAOYSA-N

物化性质

• 沸点：
  500.3±50.0 °C(Predicted)
• 密度：
  1.064±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  22
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  70.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-(4-Acetyl-3-hydroxy-2-propylphenoxy)heptane nitrile 在 sodium azide 、 氯化铵 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 23.0h， 以8%的产率得到1-{2-Hydroxy-3-propyl-4-[6-(5H-tetrazol-5-yl)-hexyloxy]-phenyl}-ethanone
  参考文献：
  名称：

  Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives

  摘要：

  A series of derivatives of 2,4-dihydroxy-3-propylacetophenone(1) were prepared and examined for their ability to block leukotriene D4 (LTD4) induced contraction of guinea pig ileum. Straight-chain carboxylic acids where the carboxyl group was separated from the acetophenone moiety by varying numbers of methylenes were evaluated, and maximum activity was obtained with the pentamethylene acid (6). Examination of ring substitution showed that the 2-propyl-3-hydroxy-4-acetyl substitution pattern was required for maximum LTD4 antagonist activity. Additional chain terminal groups were examined, and the acidic 5-tetrazolyl group separated from the acetophenone moiety by four to seven methylenes (26, 23, 27, 28) gave excellent in vitro and in vivo activities. Compound 26 (LY171883) had the best balance of in vitro and in vivo activity. It lacked bronchospastic activity at the doses administered and has been chosen for clinical evaluation.

  DOI：

  10.1021/jm00387a018
• 作为产物：
  描述：

  2,4-二羟基-3-丙基苯乙酮 在 potassium carbonate 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 35.0h， 生成 7-(4-Acetyl-3-hydroxy-2-propylphenoxy)heptane nitrile
  参考文献：
  名称：

  Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives

  摘要：

  A series of derivatives of 2,4-dihydroxy-3-propylacetophenone(1) were prepared and examined for their ability to block leukotriene D4 (LTD4) induced contraction of guinea pig ileum. Straight-chain carboxylic acids where the carboxyl group was separated from the acetophenone moiety by varying numbers of methylenes were evaluated, and maximum activity was obtained with the pentamethylene acid (6). Examination of ring substitution showed that the 2-propyl-3-hydroxy-4-acetyl substitution pattern was required for maximum LTD4 antagonist activity. Additional chain terminal groups were examined, and the acidic 5-tetrazolyl group separated from the acetophenone moiety by four to seven methylenes (26, 23, 27, 28) gave excellent in vitro and in vivo activities. Compound 26 (LY171883) had the best balance of in vitro and in vivo activity. It lacked bronchospastic activity at the doses administered and has been chosen for clinical evaluation.

  DOI：

  10.1021/jm00387a018

文献信息

• 5-substituted N-alkylated tetrazoles
  申请人：Hoffman-La Roche Inc.

  公开号：US04663332A1

  公开（公告）日：1987-05-05

  Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, and A are as described herein, are set forth. These compounds are useful as anti-allergic agents and agents for the treatment of cardiovascular diseases.

  该公式的化合物##STR1##其中R.sub.1，R.sub.2，R.sub.3和A的描述如下，这些化合物可用作抗过敏剂和心血管疾病治疗剂。
• Derivatives of 4-acetyl-3-hydroxy-2-alkyl-phenoxycarboxylic acids
  申请人：Hoffmann-La Roche Inc.

  公开号：US04672066A1

  公开（公告）日：1987-06-09

  The invention relates to compounds of the formula ##STR1## wherein R is hydrogen or lower alkyl, Y is alkylene; Z is alkylene, ##STR2## the asterisk herein denotes bonding to the substituted acetophenone; R.sub.2 is hydrogen or lower alkoxy; and n is an integer of 1 to 3; A is ##STR3## and HET is a 5-or 6- membered nitrogen containing heterocyclic group, and their acid addition salts. The compounds of formula I of the invention are useful for the treatment of allergic conditions, such as, asthma and cardiovascular diseases, such as, angina and arrhythmias.

  本发明涉及一种公式为##STR1##的化合物，其中R为氢或低级烷基，Y为烷基；Z为烷基，##STR2##此处星号表示与取代的乙酰苯酮结合；R.sub.2为氢或低级烷氧基；n为1至3的整数；A为##STR3##，HET为含有5或6个成员的氮杂环异构基团，以及它们的酸加成盐。本发明的I型化合物可用于治疗过敏症，如哮喘和心血管疾病，如心绞痛和心律失常。
• Substituted 4-acetyl-3-hydroxyphenoxy alkanoic acids
  申请人：Hoffmann-La Roche Inc.

  公开号：US04628115A1

  公开（公告）日：1986-12-09

  The invention relates to compounds of the formula ##STR1## wherein R is hydrogen or lower alkyl, Z is alkylene of 1 to 10 carbon atoms, --(C*H.sub.2).sub.3 --C.tbd.C--, --C*H.sub.2 --C.tbd.C--(CH.sub.2).sub.3 --, and --(CH.sub.2).sub.2 O].sub.n (CH.sub.2).sub.2 -- wherein n is an integer of 1 to 3, the carbon atom marked with an asterisk is linked to the phenoxy moiety, and salts thereof with pharmaceutically acceptable bases. The compounds of formula I are antagonists of slow reacting substance of anaphylaxis (SRS-A; leukotrienes C.sub.4, D.sub.4 and E.sub.4), which renders them useful as agents for the treatment of allergic conditions.

  本发明涉及公式##STR1##的化合物，其中R为氢或低碳基，Z为1到10个碳原子的烷基，--(C*H.sub.2).sub.3 --C.tbd.C--, --C*H.sub.2 --C.tbd.C--(CH.sub.2).sub.3 --和--(CH.sub.2).sub.2 O].sub.n(CH.sub.2).sub.2--其中n为1到3的整数，带星号的碳原子与苯氧基团连接，并且与药学上可接受的碱形成盐。公式I的化合物是过敏反应的缓慢反应物（SRS-A;白三烯C.sub.4、D.sub.4和E.sub.4）的拮抗剂，因此它们可用作治疗过敏性疾病的药物。
• Leukotriene antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0108592B1

  公开（公告）日：1987-09-30
• MARSHALL, WINSTON S.;VERGE, JOHN P.
  作者：MARSHALL, WINSTON S.、VERGE, JOHN P.

  DOI：——

  日期：——